Ticker Details
Actinium Pharmaceuticals, Inc Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of innovative-targeted therapies for patients with cancers lacking effective treatment options. The company's product portfolio includes Iomab-B and Actimab-A.
IPO Date:	January 1, 2003
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$33.07M
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.15 | 3.48%
Avg Daily Range (30 D):	$0.04 | 2.88%
Avg Daily Range (90 D):	$0.04 | 2.97%

Institutional Daily Volume
Avg Daily Volume:	.23M
Avg Daily Volume (30 D):	.12M
Avg Daily Volume (90 D):	.18M

Trade Size
Avg Trade Size (Sh.):	99
Avg Trade Size (Sh.) (30 D):	237
Avg Trade Size (Sh.) (90 D):	259

Institutional Trades
Total Institutional Trades:	47
Avg Institutional Trade:	$1.86M
Avg Institutional Trade (30 D):	$2.2M
Avg Institutional Trade (90 D):	$2.2M
Avg Institutional Trade Volume:	.24M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$3.11M
Avg Closing Trade (30 D):	$3.87M
Avg Closing Trade (90 D):	$3.87M
Avg Closing Volume:	431.92K

News

Oct 17, 2025 @ 6:06 PM Targeted Alpha Therapies Market to Grow at 44% CAG... Source: Bcc Research

May 25, 2025 @ 10:07 PM המועד האחרו×Å... Source: N/A

May 25, 2025 @ 10:07 PM ATNM DEADLINE NOTICE: ROSEN, A HIGHLY RECOGNIZED L... Source: N/A

May 21, 2025 @ 8:00 PM ATNM INVESTOR ALERT: Bronstein, Gewirtz & Grossman... Source: Bronstein, Gewirtz & Grossman, Llc

May 21, 2025 @ 12:00 AM ATNM INVESTOR ALERT: Kirby McInerney LLP Reminds A... Source: N/A

Financials
	TTM	Q3 2025	Q2 2025
Basic EPS	$-1.1	$-.16	$-.22
Diluted EPS	$-1.1	$-.16	$-.22
Revenue	$.09M	$.09M	$M
Gross Profit
Net Income / Loss	$-34.6M	$-5.13M	$-6.88M
Operating Income / Loss	$-37.34M	$-5.69M	$-7.5M
Cost of Revenue
Net Cash Flow	$-5.75M	$M	$M
PE Ratio

Splits
Aug 11, 2020	1:30